Literature DB >> 15167244

Primary post-traumatic mandibular reconstruction in infancy: a 10-year follow-up.

John A Girotto1, Joseph Gruss.   

Abstract

Ballistic trauma to the craniofacial skeleton combines the challenges of complex bone injury and loss with severe soft tissue injury and violation of the naso-orbital or oropharyngeal cavities. The authors report a patient who experienced a unique ballistic injury at 28 months of age that resulted in loss of the mandibular ramus and condyle. A segmental injury to the facial nerve was also identified. Primary costochondral grafting and delayed interpositional nerve grafting was undertaken. After 10 years, the patient has nearly 40 mm of opening, with only slight deviation to the injured side. Her facial nerve regeneration provides complete orbicularis oculi function, oral competence, and only slight facial asymmetry. This traumatic reconstruction differs from that of patients with hemifacial microsomia or post-traumatic/arthritic ankylosis in that the joint space itself was spared. Thus, the costochondral graft benefits from the remaining articular disk and upper disk space and is able to rotate and translate. Function and growth are adequately re-established, even in this young pediatric patient.

Entities:  

Mesh:

Year:  2004        PMID: 15167244     DOI: 10.1097/00001665-200403000-00019

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  2 in total

1.  Pediatric mandibular resection and reconstruction: long-term results with autogenous rib grafts.

Authors:  André M Eckardt; Enno-Ludwig Barth; Johannes Berten; Nils-Claudius Gellrich
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2010-03

2.  Mandibular reconstruction with autogenous non-vascularised bone graft.

Authors:  Ramat Oyebunmi Braimah; Adebayo Aremu Ibikunle; Umar Abubakar; Abdurrazaq Olanrewaju Taiwo; Muhammed Oboirien; Francis Adewale Adejobi; Terry Godwin Ndubuisi; Siddiq Abubakar
Journal:  Afr Health Sci       Date:  2019-09       Impact factor: 0.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.